

## 해외 바이오의약품 임상 현황 (2020.11.23~2020.11.29)

한국바이오의약품협회, 2020.12.1.  
출처: ClinicalTrials.gov

### ○ 미국 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04639466	A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19	COVID-19	Drug: Placebo Administration Biological: Vaccine Therapy	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT04552899	A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: PRM-151 Drug: Placebo	Hoffmann-La Roche	Phase 3
NCT04592549	This is a Phase 1 Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of ADM03820, a Monoclonal Antibody Cocktail Being Tested for the Treatment and Prevention of COVID-19	SARS-CoV-2	Drug: ADM03820 Other: Placebo	Ology Bioservices Enabling Biotechnologies (EB)	Phase 1
NCT04644120	Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 Moves Through the Body of Adult Participants Hospitalized With Coronavirus Disease 2019 (COVID-19)	CoronaVirus Disease-2019 (COVID-19)	Drug: ABBV-47D11 Drug: Placebo for ABBV-47D11	AbbVie	Phase 1
NCT04460885	A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before	Diabetes Mellitus, Type 2	Drug: Insulin icodec Drug: Insulin glargine	Novo Nordisk A/S	Phase 3

### ○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04460885	A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before	Diabetes Mellitus, Type 2	Drug: Insulin icodec Drug: Insulin glargine	Novo Nordisk A/S	Phase 3

### ○ 프랑스 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04348045	Phase II Study to Evaluate Maintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients	Metastatic Pancreatic Adenocarcinoma	Drug: Arm A - Olaparib Drug: ARM B - durvalumab plus selumetinib Drug: ARM C FOLFIRI	GERCOR - Multidisciplinary Oncology Cooperative Group AstraZeneca	Phase 2

### ○ 독일 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04641312	A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes	Healthy Type 2 Diabetes	Drug: LY3457263 Drug: Dulaglutide Drug: Placebo	Eli Lilly and Company	Phase 1
NCT04195373	A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract	Gastrointestinal Cancer	Biological: TMV-018 + 5-FC Biological: TMV-018 + anti-PD-1 Biological: TMV-018 + 5-FC + anti-PD-1	Themis Bioscience GmbH Assign Data Management and Biostatistics GmbH SSS International Clinical Research GmbH	Phase 1

### ○ 중국 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04635527	A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma	Hepatocellular Carcinoma	Drug: IBI318 Procedure: cTACE Drug: placebo	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1
NCT04600817	A Study to Evaluate the Efficacy and Safety of TJ107 in Lymphopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)	Newly Diagnosed Glioblastoma	Drug: TJ107 Drug: TJ107 placebo	I-Mab Biopharma Co. Ltd.	Phase 2
NCT04557020	Adding Neoadjuvant and Adjuvant PD-1 Inhibitor to Neoadjuvant Chemotherapy Plus Concurrent Chemoradiotherapy in the Treatment of High-risk Nasopharyngeal Carcinoma	Nasopharyngeal Carcinoma	Drug: PD-1 antibody Drug: Gemcitabine Drug: cis Platinum Radiation: IMRT	Jiangxi Provincial Cancer Hospital	Phase 3

### ○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04460885	A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before	Diabetes Mellitus, Type 2	Drug: Insulin icodec Drug: Insulin glargine	Novo Nordisk A/S	Phase 3